Alnylam Pharmaceuticals Inc., of Cambridge, Mass. won FDA breakthrough status for givosiran (ALN-AS1), the company’s investigational RNAi therapy targeting aminolevulinic acid synthase 1 for the prophylaxis of attacks in patients with acute hepatic porphyria.